Ozempic’s Lost Revolution: Eli Lilly Ousts Novo Nordisk’s Market Leadership

A new weight‑loss titan’s shadow cast the most unexpected financial upheaval of 2024: Eli Lilly eclipsed Novo Nordisk’s $12.8 billion Ozempic revenue with $18.4 billion of tirzepatide sales.

A New Titan, an Old Leader’s Brief Decline

■Ozempic generated $12.8 billion in 2023, but tirzepatide surged to $18.4 billion in 2024.

■Novo Nordisk’s net‑margin fell from 18.5 % to 15.7 %, while Eli Lilly rose to 22.3 %.

■On the NASDAQ, Novo Nordisk shares slid 4.2 %; Eli Lilly shares climbed 3.1 %.

Lilly’s Strategic Move: 4.5 % Market‑Share Gain

■Eli Lilly captured 4.5 % of the GLP‑1 market with tirzepatide.

■The company plans a $6.3 billion drug launch in 2024.

■R&D spend for 2024 is set at $3.2 billion.

Color Shifts in Finance: $18.4 Billion Sales

■Novo Nordisk’s total drug sales dropped from $27.4 billion to $25.7 billion in 2024.

■Eli Lilly’s tirzepatide sales broke records at $18.4 billion.

■Market cap for Eli Lilly reached $190 billion; Novo Nordisk stayed around $210 billion.

Investors’ Focus: Stock Movements and Outlook

■Eli Lilly shares rose 7.8 % in 2024, while Novo Nordisk fell 2.9 %.

■Analysts forecast tirzepatide could hit $25 billion revenue by 2025.

■Novo Nordisk is accelerating new GLP‑1 candidates as Ozempic patents near expiry.

The market is witnessing a rapid reshaping of the GLP‑1 arena. Eli Lilly’s aggressive pricing and swift distribution network are challenging Novo Nordisk’s long‑term strategy, signalling a new era where price competition and innovation march hand in hand.